The key takeaways for this program are:
- Understanding the Prometheus decision and what the Supreme Court did and did not say;
- Understanding the question at issue in Myriad and how it is similar—and different—from that decided in Prometheus;
- Learning possible patent claim strategies to protect personalized medicine methods and biotechnology inventions under the new paradigm;
- Reviewing the U.S. Patent Office Guidance to Examiners, issued shortly after the Supreme Court decided Prometheus; and
- Discussing Options for strengthening already granted patents.
People
Related Insights
04 June 2025
Events
Health Care Organizations: Reduce Cybersecurity Threats
Foley partner Jennifer Urban, chair of the firm’s Cybersecurity & Data Privacy Area of Focus, is speaking in Moss Adams’ upcoming webinar titled “Health Care Organizations: Reduce Cybersecurity Threats” on June 4.
21 May 2025
Tariff & International Trade Resource
What Every Multinational Company Should Know About … Customs Enforcement and False Claims Act Risks (Part III)
We complete the series on “Customs Enforcement and False Claims Act Risks” with Part III, which focuses on preparing for the most common FCA risks arising from improper management of import operations.
02 June 2025
Events
Biotech Panel Discussion & Happy Hour
Join Foley & Lardner LLP along with Biotech XYZ for an engaging evening event featuring a dynamic panel discussion and a lively happy hour.